Key Information Document

Purpose

This information sheet provides you with key information about this investment product. It is not marketing material. This information is required by law to help you understand the type of product, the risks and costs involved as well as the potential profits and losses, and to help you compare it with other products.

Product

Product name	**UBS (Lux) Equity Fund - Biotech (USD), unit class P-acc, USD**
Manufacturer	**UBS Asset Management (Europe) S.A.**
ISIN	LU0069152568
Telephone number	For more information, please call +352 27 1511.
Website	www.ubs.com/funds

The Commission de Surveillance du Secteur Financier (CSSF) is responsible for supervising UBS Asset Management (Europe) S.A. in relation to this Key Information Document.
This PRIIP is authorized in Luxembourg.
UBS Asset Management (Europe) S.A. is authorised in Luxembourg and regulated by the Commission de Surveillance du Secteur Financier (CSSF).
Date of production of the KID: 13 March 2026.

What is this product?

Type

UBS (Lux) Equity Fund is an undertaking for collective investment in transferable securities (UCITS) with the legal status of a Fonds Commun de Placement (FCP) established under Part I of the Luxembourg Law of 2010 relating to undertakings for collective investment.

Term

The Product does not have a maturity date (the Product has been established for an indefinite period of time). The Manufacturer may terminate the Product early. The amount you will receive upon early termination may be less than the amount you invested.
The recommended holding period (RHP) is displayed in the section "How long should I hold it and can I take money out early?".

Objectives

The actively managed investment fund invests worldwide primarily in the shares of companies related to the biotechnology sector.
Based on sound analysis by our investment specialists worldwide, the fund manager combines carefully selected equities of various companies from different countries and segments in this sector with the aim of taking advantage of interesting return opportunities while keeping risks under control.
The portfolio manager has discretion to construct the portfolio and is not bound by the benchmark in terms of equities and weighting.
The investment fund is actively managed in relation to the benchmark MSCI US Investable Market Biotechnology 10/40 (net div. reinvested).
The benchmark is used for portfolio composition, performance comparison and risk management.
This sub-fund promotes environmental and/or social features but does not pursue a sustainable investment objective.
The return of the fund depends primarily on equity market development and their exchange rate fluctuations, as well as dividend payments.
The income from this share class is reinvested (reinvestment).

Intended retail investor

This fund applies to retail investors with a basic financial understanding, who can accept a possible loss on the investment amount. The fund is aimed at growing the investment value, while granting daily access to the capital under normal market conditions. With their investment in this fund, investors can satisfy long term investment needs. The fund is suited to be acquired by the target client segments without any restriction of the distribution channel or platform.

Depositary

UBS Europe SE, Luxembourg Branch

Further Information

Information on Biotech (USD) and the available unit classes as well as the full prospectus and the current annual or semi-annual reports and other information can be obtained free of charge from the fund management company, the central administration agent, the depositary, the custodian bank, the fund distributors or online at www.ubs.com/funds. The current price is available at www.ubs.com/funds

What are the risks and what could I get in return?

Indicator



The risk indicator assumes you keep the product for 7 years.
The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.
We have classified this product as 5 out of 7, which is a medium-high risk class.
This rates the potential losses from future performance at a medium-high level. The past may be a poor predictor of the future and, hence, the actual risk of losing money may vary significantly.

The product may be exposed to further risk factors such as operational, political and legal risks which are not included in the summary indicator. Please refer to the prospectus for more detail.

This product does not include any protection from future market performance so you could lose some or all of your investment.
If we are not able to pay you what is owed, you could lose your entire investment.

Performance Scenarios

What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.
The unfavourable, moderate and favourable scenarios shown are illustrations using the worst, average, and best performances of the product over the last 12 years. Markets could develop very differently in the future.

Recommended holding period:		**7 Years**	
Example Investment:		**USD 10 000**	
		If you exit after 1 year	**If you exit after 7 years**
Scenarios			
Minimum	**There is no minimum guaranteed return. You could lose some or all of your investment.**		
Stress	**What you might get back after costs**	USD 3 470	USD 1 860
	Average return each year	-65.3%	-21.4%
Unfavourable	**What you might get back after costs**	USD 6 470	USD 8 640
	Average return each year	-35.3%	-2.1%
Moderate	**What you might get back after costs**	USD 9 830	USD 12 380
	Average return each year	-1.7%	3.1%
Favourable	**What you might get back after costs**	USD 14 840	USD 19 620
	Average return each year	48.4%	10.1%

The stress scenario shows what you might get back in extreme market circumstances.
The figures shown include all costs of the product itself. The figures do not take account of your personal tax situation, which can also have an impact on how much you receive back.
Unfavourable scenario: This type of scenario occurred for an investment between 2015 and 2022.
Moderate scenario: This type of scenario occurred for an investment between 2017 and 2024.
Favourable scenario: This type of scenario occurred for an investment between 2014 and 2020.

What happens if UBS Asset Management (Europe) S.A. is unable to pay out?

Losses are not covered by any investor compensation or guarantee scheme. In addition, UBS Europe SE, Luxembourg Branch, the depositary of the Fund responsible for safekeeping its assets (the "Depositary"), is subject to a potential default risk in the event that the assets of the Fund held with the Depositary are lost. However, this risk of default is limited as the Custodian is required by law and regulation to segregate its own assets from the Fund's assets. The Custodian shall be liable to the Fund or the Fund's investors for any loss of a financial instrument held in custody by the Custodian or its delegate, unless the Custodian can demonstrate that the loss resulted from an external event beyond its control.

What are the costs?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

Costs over time

The table shows the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product and how well the product does. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.
We have assumed:
- In the first year you would get back the amount that you invested (0% annual return). For the other holding periods, we have assumed that the product performs as shown in the moderate scenario.
- 10 000 USD is invested.

	If you exit after 1 year	If you exit after 7 years
Total costs	USD 734	USD 2 203
Annual cost impact (*)	7.3%	3.1% each year

(*) This illustrates how costs reduce your return each year over the holding period. For example, it shows that if you exit at the recommended holding period your average return per year is projected to be 6.2% before costs and 3.1% after costs.
We may share part of the costs with the person selling you the product to cover the services they provide to you. They will inform you of the amount.

Composition of costs

One-off costs upon entry or exit		If you exit after 1 year
Entry costs	5.0% of the amount you pay in when entering this investment. This is the most you will be charged. The person selling you the product will inform you of the actual charge.	Up to USD 500
Exit costs	We do not charge an exit fee for this product, but the person selling you the product may do so.	USD 0
Ongoing costs taken each year		
Management fees and other administrative or operating costs	2.1% of the value of your investment per year. This is an estimate based on actual costs over the last year.	USD 211
Transaction costs	0.2% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.	USD 25
Incidental costs taken under specific conditions		
Performance fees	There is no performance fee for this product.	USD 0

The figures shown here do not include any additional charges that may be levied by your distributor, adviser or any "insurance wrapper" into which the fund may be placed. Additional information on costs can be found in the sales prospectus at www.ubs.com/funds

How long should I hold it and can I take money out early?

Recommended holding period: 7 Year(s)

The recommended holding period for this product is 7 year(s). This is our recommended holding period based on the risk and expected return with the product. Please note that the expected return is not guaranteed. The more the actual holding period deviates from the recommended holding period for the product, the more your actual return will also deviate from the product assumptions. Depending on your needs and limitations, a different holding period may be suitable for you. Consequently, we recommend that you discuss this issue with your customer service representative.
In principle, investors may ask the Management Company to redeem their units on any business day in Luxembourg.

How can I complain?

If you have a complaint about the product, the producer of the product or the person who recommended or sold you the product, please contact your customer service representative or contact us at www.ubs.com/ame-regulatorydisclosures
UBS Asset Management (Europe) S.A., The Complaint handling Director, 33A, Avenue J.F. Kennedy, B.P.91, L-2010 Luxembourg, Email: OL-UBSAME-complainthandling@ubs.com

Other relevant information

Information on historical performance and calculations of past performance scenarios can be found at www.ubs.com/funds.

UBS